FDA’s Quality Management Maturity Program – Why should CDMOs adhere to the new CDER’s Rati

Comprehensive mRNA Solutions

The M.O. Behind Choosing a CDMO: Three Considerations for New Drug Developers

A Year In Review — Curia’s Contributions to Science in 2020

The Shift Toward Western Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix

COVID-19: Updates from Curia

Selected AMRI Publications and Patents from 2005–2019

2019: A Year in Review — AMRI’s Contributions to Science